ADMA Q4 2021 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M+89.0% YoY

Gross Profit

$4M13.3% margin

Operating Income

-$13M-50.0% margin

Net Income

-$17M-63.1% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

+27.6%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$37M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$276M

Total Liabilities

$135M

Stockholders' Equity

$141M

Cash & Equivalents

$51M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$14M	+89.0%
Gross Profit	$4M	-$5M	+168.1%
Operating Income	-$13M	-$17M	+23.4%
Net Income	-$17M	-$19M	+14.2%

Revenue Segments

Product Revenue

$26M100%

License Revenue

$35,7090%